These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32382656)

  • 21. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.
    Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ
    Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical administration of oxaliplatin for patients previously treated for refractory advanced or recurrent colorectal cancer].
    Takahari D; Tsuji Y; Sagawa T; Honda K; Sumiyoshi T; Yoshizaki N; Kuroiwa G; Kondo H
    Gan To Kagaku Ryoho; 2006 Jan; 33(1):49-54. PubMed ID: 16410698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
    Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
    Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
    Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
    EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1.
    Liu H; Yin Y; Hu Y; Feng Y; Bian Z; Yao S; Li M; You Q; Huang Z
    Pathol Res Pract; 2016 Jul; 212(7):643-9. PubMed ID: 27173050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells.
    Shang J; Yang F; Wang Y; Wang Y; Xue G; Mei Q; Wang F; Sun S
    J Cell Biochem; 2014 Apr; 115(4):772-84. PubMed ID: 24249161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
    Lévi FA; Zidani R; Vannetzel JM; Perpoint B; Focan C; Faggiuolo R; Chollet P; Garufi C; Itzhaki M; Dogliotti L
    J Natl Cancer Inst; 1994 Nov; 86(21):1608-17. PubMed ID: 7932825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
    Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
    Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The long non-coding RNA HOTAIRM1 suppresses cell progression via sponging endogenous miR-17-5p/ B-cell translocation gene 3 (BTG3) axis in 5-fluorouracil resistant colorectal cancer cells.
    Ren T; Hou J; Liu C; Shan F; Xiong X; Qin A; Chen J; Ren W
    Biomed Pharmacother; 2019 Sep; 117():109171. PubMed ID: 31261026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
    Feng C; Zhang L; Sun Y; Li X; Zhan L; Lou Y; Wang Y; Liu L; Zhang Y
    Biomed Pharmacother; 2018 May; 101():945-952. PubMed ID: 29635904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenoxodiol sensitizes metastatic colorectal cancer cells to 5-fluorouracil- and oxaliplatin-induced apoptosis through intrinsic pathway.
    Yaylaci E; Onen HI; Yar Saglam AS
    EXCLI J; 2020; 19():936-949. PubMed ID: 32665777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
    Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma.
    Martoni A; Mini E; Pinto C; Nobili S; Gentile AL; Dentico P; Angelelli B; Scicolone S; Piana E; Mazzei T
    Ann Oncol; 2001 Apr; 12(4):519-24. PubMed ID: 11398887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
    Abad A; Massutí B; Gallego J; Yuste AL; Manzano JL; Carrato A; Antón A; Marfa X; Diaz-Rubio E;
    Anticancer Drugs; 2004 Jun; 15(5):469-71. PubMed ID: 15166620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer.
    Osumi H; Shinozaki E; Suenaga M; Wakatsuki T; Nakayama I; Matsushima T; Ogura M; Ichimura T; Takahari D; Chin K; Nagasaki T; Konishi T; Akiyoshi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Yamaguchi K
    PLoS One; 2017; 12(5):e0176745. PubMed ID: 28562679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the individualization of the first-line chemotherapy for advanced colorectal cancer based on collagen gel droplet-embedded drug sensitivity test.
    Ochiai T; Nishimura K; Watanabe T; Kitajima M; Nakatani A; Nagayasu K; Naito S; Sato T; Kishine K; Abe Y; Hara C; Yamada S; Mashiko S; Nagaoka I
    Oncol Lett; 2017 Nov; 14(5):6045-6052. PubMed ID: 29113244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-138 Suppresses the PDK1 Expression to Decrease the Oxaliplatin Resistance of Colorectal Cancer.
    Wang Y; Zhang D; Li Y; Fang F
    Onco Targets Ther; 2020; 13():3607-3618. PubMed ID: 32431512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
    Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
    Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer.
    Rosati G; Rossi A; Tucci A; Pizza C; Manzione L
    Ann Oncol; 2001 May; 12(5):669-74. PubMed ID: 11432626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
    J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.